Can psychedelic compounds play a part in drug dependence therapy?
The British Journal of Psychiatry 2015 DOI: 10.1192/bjp.bp.114.148031 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Patients with substance dependency |
| Interventions | Psilocybin Ketamine Ibogaine Ayahuasca |
| Topics | Ayahuasca Ketamine Psilocybin Addiction Psychedelic-assisted therapy |
| Keywords | Hallucinogen Drug Psychotherapist Pharmacology |
| Citations | 58 |
| Key findings | Psychedelic drug therapy is being revisited in psychiatry for treating drug dependence, though clinical and legal limitations remain. |
Abstract
Summary After a 40-year hiatus there is now a revisiting of psychedelic drug therapy throughout psychiatry, with studies examining the drugs psilocybin, ketamine, ibogaine and ayahuasca in the treatment of drug dependence. Limitations to these therapies are both clinical and legal, but the possibility of improving outcomes for patients with substance dependency imposes an obligation to research this area.